BioSpace News Archive

Walgreens announced the launch of myWalgreens, a complete reinvention of its customer loyalty program to offer customers extensive new benefits, including the fastest same-day retail pickup offering available today*.

ChemoCentryx, Inc., announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences

Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that the company has signed a worldwide Licensing and Development Agreement with a consortium of partners in China to utilize the Ii-Key vaccine platform technology from Generex subsidiary NuGenerex Immuno-Oncology (NGIO) for developing a vaccine against the G4 EA H1N1 swine influenza that is rapidly emerging in China.

Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming, today announced that its AditxtScore™laboratory operations for immune monitoring has secured CLIA certification, allowing for the launch of AditxtScore™for COVID-19 as a Laboratory Developed Test (LDT).

Syngene International and Deerfield Discovery and Development Corporation (3DC), the drug discovery and development subsidiary of Deerfield Management Company (Deerfield), have signed an agreement to collaborate to advance therapeutic discovery projects, from target validation through to pharmacological proof of concept and preclinical evaluation

JFI Medical LLC, a group of nationally accomplished African American physicians and professionals dedicated to developing strategies for affording underserved communities’ access to premium medical products and services, today announced, with top 100 U.S. law firm Akerman LLP, the appointment of Akerman partner, William P. Heller, as its Chief Legal Advisor

DeBogy Molecular, a bio-engineering startup centered on anti-microbial surface modification technology, announced its acceptance into the University of Connecticut’s Technology Incubation Program (TIP)

Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that the European Commission (EC) has granted Orphan Drug designation for zanidatamab, the company’s investigational HER2-targeted bispecific antibody, in patients with gastric cancer.

Sapience Therapeutics , Inc., a clinical stage biotechnology company focused on discovering and developing peptide therapeutics to address difficult to treat oncology indications, announced today that it has renewed its research collaboration agreement with the University of Bath for the discovery of new therapeutic agents. “The continuation of this drug discovery partnership with Dr. Jody Mason and the University of Bath speaks to the succ

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will present a company overview at the Piper Sandler 32 nd Annual Healthcare Conference, being held virtually on December 1 - 3, 2020. This presentation will be available on demand for registered attendees. Abo